Merck
CN

SML1175

Sigma-Aldrich

罗咪酯肽

≥98% (HPLC)

登录查看公司和协议定价

别名:
FK228, FR901228, L-缬氨酸, N-((3S,4E)-3-羟基-7-巯基-1-氧代-4-庚基)-D-戊基-D-半胱氨酸-(2Z)-2-氨基-2-丁烯氧基-, (4-1)-内酯,环状(1-2)-二硫化物, 环[(2Z)-2-氨基-2-丁烯酰基-L-戊基-(3S,4E)-3-羟基-7-巯基-4-庚烯酰基-D-戊基-D-半胱氨酰]环状(35)-二硫化物, 缩酚酸肽
经验公式(希尔记法):
C24H36N4O6S2
分子量:
540.70
MDL编号:
PubChem化学物质编号:
NACRES:
NA.77

质量水平

检测方案

≥98% (HPLC)

形式

powder

颜色

white to beige

溶解性

DMSO: 25 mg/mL, clear

储存温度

−20°C

SMILES string

O=C(N/C(C(N[C@@H](C(C)C)C(O[C@@]1([H])CC2=O)=O)=O)=C\C)[C@@H](CSSCC/C=C/1)NC([C@H](N2)C(C)C)=O

InChI

1S/C24H36N4O6S2/c1-6-16-21(30)28-20(14(4)5)24(33)34-15-9-7-8-10-35-36-12-17(22(31)25-16)26-23(32)19(13(2)3)27-18(29)11-15/h6-7,9,13-15,17,19-20H,8,10-12H2,1-5H3,(H,25,31)(H,26,32)(H,27,29)(H,28,30)/b9-7+,16-6-/t15-,17-,19-,20+/m1/s1

InChI key

OHRURASPPZQGQM-GCCNXGTGSA-N

生化/生理作用

罗米地辛可促进细胞凋亡,同时阻碍神经胶质瘤模型中肿瘤的生长。
罗米地辛是HDAC1和HDAC2的一种非常有效的天然前药抑制剂,可被谷胱甘肽转化为活性形式。罗米地辛对HDAC1和HDAC2的IC50 值分别为36 nM和47 nM。它可杀死过表达Bcl-2和Bcl-XL的淋巴瘤细胞系,并已被批准用于治疗皮肤T细胞淋巴瘤(CTCL)和外周T细胞淋巴瘤,以及多种其他癌症。

储存分类代码

11 - Combustible Solids

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable


分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

为方便起见,与您过往购买产品相关的文件已保存在文档库中。

访问文档库

难以找到您所需的产品或批次号码?

在网站页面上,产品编号会附带包装尺寸/数量一起显示(例如:T1503-25G)。请确保 在“产品编号”字段中仅输入产品编号 (示例: T1503).

示例

T1503
货号
-
25G
包装规格/数量

其它示例:

705578-5MG-PW

PL860-CGA/SHF-1EA

MMYOMAG-74K-13

1000309185

输入内容 1.000309185)

遇到问题?欢迎随时联系我们技术服务 寻求帮助

批号可以在产品标签上"批“ (Lot或Batch)字后面找到。

Aldrich 产品

  • 如果您查询到的批号为 TO09019TO 等,请输入去除前两位字母的批号:09019TO。

  • 如果您查询到的批号含有填充代码(例如05427ES-021),请输入去除填充代码-021的批号:05427ES。

  • 如果您查询到的批号含有填充代码(例如 STBB0728K9),请输入去除填充代码K9的批号:STBB0728。

未找到您寻找的产品?

部分情况下,可能未在线提供COA。如果搜索不到COA,可在线索取。

索取COA

A phase I/II trial of the histone deacetylase inhibitor romidepsin for adults with recurrent malignant glioma: North American Brain Tumor Consortium Study 03-03.
Iwamoto F M, et al.
Neuro-Oncology, 13(5), 509-516 (2011)
Sara Moron-Lopez et al.
AIDS (London, England), 33(3), 425-431 (2018-12-12)
Reversing HIV-1 latency has been suggested as a strategy to eradicate HIV-1. We investigated the effect of romidepsin on the HIV transcription profile in participants from the REDUC part B clinical trial. Seventeen participants on suppressive antiretroviral therapy were vaccinated
Florencia Cayrol et al.
Nature communications, 8, 14290-14290 (2017-01-31)
Peripheral T-cell lymphomas (PTCL) are aggressive diseases with poor response to chemotherapy and dismal survival. Identification of effective strategies to target PTCL biology represents an urgent need. Here we report that PTCL are sensitive to transcription-targeting drugs, and, in particular
Sina Jostes et al.
Journal of cellular and molecular medicine, 21(7), 1300-1314 (2016-12-28)
Type II testicular germ cell cancers (TGCT) are the most frequently diagnosed tumours in young men (20-40 years) and are classified as seminoma or non-seminoma. TGCTs are commonly treated by orchiectomy and chemo- or radiotherapy. However, a subset of metastatic
Anna Otte et al.
International journal of oncology, 49(6), 2453-2463 (2016-10-18)
Chemotherapeutic drug testing of SCCOHT-1 and BIN-67 tumor cells revealed synergistic growth-inhibition of >95% in vitro with a combination of foretinib and FK228. Application of this drug combination in vivo in NODscid mice-induced SCCOHT-1GFP tumors was associated with ~6-fold reduction in

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门